Inovio Pharmaceuticals Inc. (INO), a biotechnology company focused on DNA-based immunotherapies and vaccines, is drawing renewed investor attention following a series of clinical and regulatory developments that may shape its strategic trajectory heading into 2026.
DMAb Data Published in Nature Medicine
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com